Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK awards £4million for pharmacogenetic screening research and development:

This article was originally published in Clinica

Executive Summary

The UK's Department of Health today announced six pharmacogenetics research projects that will receive grants totalling £4m ($7.4m). One of the topics being funded from the £50m national genetics strategy is universal pre-surgery screening for predisposition to the potentially fatal malignant hyperthermia, as a reaction to a commonly used general anaesthetic. The other projects are on tests to assess the risk of adverse reactions to drug therapies, including: dosification of anthracyclines (cancer drug), which can cause severe heart damage; patient response to epilepsy drugs and anti-clotting agents; susceptibility to liver injury from penicillin and anti-turberculosis medicines; potential adverse reactions to inflammatory disease treatments.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel